Knowledge center

Worthmed®’s curated hub of articles exploring health innovation concepts across clinical, technology, and business/market dimensions.

Sequence of blocks with one highlighted element, representing the need for continuous monitoring and reliability after launch.

Clinical use and standard of care: what “maturity” means after launch

After launch, maturity is about sustained performance, workflow integration, and evidence that holds up over time across contexts.
Minimal illustration of four elements with one highlighted, representing different stakeholder perspectives and the need to align value across them.

Stakeholder value: how to prove value to clinicians, managers, payers

Adoption requires different proof packages for different stakeholders. Value is not one metric, but a set of decision drivers.
Abstract yellow triangle marking a turning point, representing the decision between using retrospective data and conducting prospective validation.

Real-world evidence: when retrospective data is enough, and when it is not

Retrospective data can be the fastest way to build credibility, but it is not always sufficient. The right choice depends on the decision you need to unlock.
Progressive transformation from square to circle, representing how a TRL story becomes more refined, coherent, and credible over time.

How to write a TRL story that matches your workplan and budget

strong TRL story is a project logic: starting point, proof steps, outputs, and end point. It must match time, methods, and budget.
Minimal illustration of three circles aligned in sequence with the final circle marked by a checkmark, representing progression toward EU funding readiness.

EU funding readiness: what reviewers look for in your pathway to impact

Reviewers fund credible pathways, not only good ideas. The strongest proposals connect TRL, evidence, workplan, and impact logically.
Minimal funnel with three narrowing layers, illustrating the progression from broad interest to selective purchase decisions.

From “interest” to “purchase”: what changes in your proof as you scale

Early interest is easy. Purchase requires proof that reduces operational and financial risk, with clear implementation and impact evidence.
Tilted balance showing clinical value outweighing user experience, highlighting the tension and trade-offs between usability and clinical impact.

Clinical value is not UX. What stakeholders call “benefit”

Good UX helps adoption, but clinical value is measured by outcomes, decisions, and workflow impact. Confusing the two blocks scale.
Minimal illustration of a three-column vertical bar chart, representing how evidence strategy evolves across different technology readiness levels.

Evidence strategy by TRL: what to prove at each stage

Evidence is not one big study at the end. It is a staged plan where each TRL step has a proof goal, method, and decision outcome.
Minimal illustration of two points connected by an upward arrow, highlighting a gap between clinical and technical maturity levels, representing uneven progress across dimensions of technology readiness.

The multi-dimensional trap: you can be TRL6 technically and TRL2 clinically

Digital health maturity is not one number. Teams often overbuild tech while under-proving clinical value, which blocks funding and scale.
Minimal illustration comparing a short bar labeled pilot success with a much longer bar representing meaningful impact, highlighting that proof of concept is not the same as proof of value.

Proof-of-Value: the missing step between pilots and adoption

Many pilots succeed yet never scale because they prove functionality, not value. Proof-of-Value connects evidence to adoption decisions.
Minimal illustration of a dashed square with a question mark transforming into a solid square with a checkmark, representing the shift from self-reported maturity to validated proof.

TRL is self-reported. Here is how to prove it credibly

TRL claims are often optimistic. Credibility comes from linking each TRL statement to concrete proof and decision-grade evidence.
Minimal illustration of a rising bar chart showing increasing maturity across technology readiness levels, representing progression from early-stage concepts to fully mature solutions.

TRL in digital health: why maturity is your best funding and go-to-market tool

TRL is not paperwork. It is the shared language that reduces risk for funders and buyers by making your next proof step clear.
Contact usPrivacy PolicyTerms and Conditions
© 2026 Worthmed. All rights reserved.